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Epstein-Barr virus (EBV) causesBurkitt, Hodgkin, and
post-transplant B cell lymphomas. How EBV re-
models metabolic pathways to support rapid B cell
outgrowth remains largely unknown. To gain insights,
primary human B cells were profiled by tandem-
mass-tag-based proteomics at rest and at nine time
points after infection; >8,000 host and 29 viral pro-
teinswere quantified, revealingmitochondrial remod-
eling and induction of one-carbon (1C) metabolism.
EBV-encoded EBNA2 and its target MYC were
required for upregulation of the central mitochondrial
1C enzyme MTHFD2, which played key roles in EBV-
driven B cell growth and survival. MTHFD2 was crit-
ical for maintaining elevated NADPH levels in infected
cells, and oxidation of mitochondrial NADPH dimin-
ished B cell proliferation. Tracing studies under-
scored contributions of 1C to nucleotide synthesis,
NADPH production, and redox defense. EBV upregu-
lated import and synthesis of serine to augment 1C
flux. Our results highlight EBV-induced 1Cas a poten-Context and Significance
Epstein-Barr virus (EBV) is a herpes family virus, which is comm
kissing disease) and a rare number of blood cancers such as B
Harvard Medical School investigated a neglected aspect of EB
nutrient acquisition and cellular proliferation. They show that E
folate metabolism’’ pathway, normally used in embryonic deve
antioxidant support needed for cancer cell growth. The work
dependent mitochondrial 1C metabolic inhibitors for the treat
Cell Metabolism 30, 539–555, Septe
This is an open access article undtial therapeutic target and provide a newparadigm for
viral onco-metabolism.
INTRODUCTION
Epstein-Barr virus (EBV) is a gamma-herpes virus that success-
fully colonizes the B cell compartment of 95% of adults world-
wide and was the first identified human tumor virus. EBV is the
etiological agent of infectious mononucleosis (IM) and is associ-
ated with 1% of all human cancers worldwide, including multi-
ple B cell malignancies (Longnecker et al., 2013) such as
endemic Burkitt lymphoma (BL), Hodgkin lymphoma (HL),
diffuse large B cell lymphoma (DLBCL) of the elderly, and primary
central nervous system lymphoma (Shannon-Lowe et al., 2017).
EBV is also the major cause of post-transplant lymphoprolifera-
tive disorder (PTLD), where viral oncoproteins drive uncontrolled
B cell growth in 1%–20% of solid organ and stem-cell trans-
plants (LaCasce, 2006; Green and Michaels, 2013).
A hallmark of EBV is its ability to transform primary human
B cells into hyperproliferating blasts followed ultimately by
establishment of latency, in which viral oncoproteins are ex-
pressed, but infectious virus is not produced. Through a geneti-
cally encoded viral program comprising at least three phasesonly associated with infectious mononucleosis (‘‘mono’’ or
cell lymphomas. Researchers at Cambridge University and
V infection: how EBV remodels B cell pathways to facilitate
BV infection highjacks the B cell mitochondria and the ‘‘1C
lopment, to provide the complex cellular building blocks and
provides an attractive rationale for developing novel folate-
ment of B lymphomas.
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Figure 1. Temporal Proteomic Profiling of EBV B Cell Transformation Reveals Dramatic Metabolic Remodeling
(A) Schematic of experimental workflow. Primary human B cells (3 biological replicates, each consisting of 4 independent donors) were analyzed prior to and at
nine time points after EBV infection. CD23+ EBV-infected cells were enriched by fluorescence-activated cell sorting (FACS). WCL, whole-cell lysate.
(B) Representative immunoblots (n = 3) of EBV nuclear antigens (EBNAs), latent membrane proteins (LMPs), and load-control DDX1 of newly infected primary
B cells at the indicated days post-infection (DPI).
(C) k-means clustering (k = 6) of the 6,500 B cell proteins quantified in all three replicates based on averaged relative abundances. Representative expression
profiles are shown to the right of each k-means cluster. To determine the actual number of distinct classes of host protein expression, the k-means approach was
used with 1–12 classes to cluster viral proteins, and the summed distance of each protein from its cluster centroid was calculated (see Figure S1D).
(legend continued on next page)
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in vitro (Nikitin et al., 2010), EBV subverts major B cell activation
pathways normally operative in lymph node germinal center
reactions (Thorley-Lawson, 2015). First, EBV dramatically re-
models B cell architecture over 72 h post-infection, where
Epstein-Barr virus nuclear antigen 2 (EBNA2) and its coactivator
EBNA-leader protein (EBNA-LP) act in concert to convert small
quiescent cells into large activated blasts. Next, EBNA2 drives
MYC expression and hyperproliferation reminiscent of BL, the
fastest-growing human tumor (Molyneux et al., 2012), with
mitosis every 8–12 h (Nikitin et al., 2010). Finally, EBNA2 induces
expression of oncogenic EBNA3s and latent membrane proteins
(LMPs). LMP1 mimics CD40 signaling to constitutively activate
NF-kB (Wang et al., 2017; Kieser and Sterz, 2015), whereas
LMP2A subverts the B cell receptor pathway to activate the
PI3K-AKT-mTOR pathway (Cen and Longnecker, 2015). Growth
transformation in vitro culminates in the generation of immortal-
ized lymphoblastoid cell lines (LCLs), which serve as a major
model of EBV-driven lymphoblastic lymphomas.
Each B cell transformation phase necessitates widespread re-
modeling of host metabolic pathways. Metabolic stress is a
major barrier to EBV-induced B cell transformation; newly in-
fected cells that fail to transform undergo growth arrest charac-
terized bymitochondrial dysfunction and attenuatedmammalian
target of rapamycin (mTOR) signaling (McFadden et al., 2016).
Metabolic remodeling has not been systematically investigated
during EBV-driven B cell transformation or, more generally, in
primary human B cell activation. While viral genes essential for
B cell transformation have been identified, their global effects
on B cell metabolism are poorly understood. There is little knowl-
edge regarding the mechanisms by which EBV induces or
activates key metabolic pathways to transform a quiescent B
lymphocyte into a lymphoblast. Likewise, the roles of metabolic
pathways in establishing and/or maintaining continual lympho-
blastoid B cell growth are not well characterized.
A systematic quantitative analysis of temporal changes in host
and viral proteins over the course of transformation in primary
human B cells could provide a comprehensive understanding
of EBV-driven metabolic reprogramming and give insights
into pathways important in EBV-driven malignancies. Here, we
used multiplexed tandem-mass tag (TMT)-based proteomics
to measure >8,000 host proteins and 29 viral proteins over
nine time points of infection of primary human B cells and in un-
infected cells (Weekes et al., 2014). We found that EBV remodels
B cell mitochondria and that mitochondrial one-carbon (1C)
metabolism was one of the most highly induced pathways. 1C
plays key roles in supporting rapid cell growth in embryonic
development (Christensen and Mackenzie, 2008; Patel et al.,
2005; Di Pietro et al., 2002; Patel et al., 2003), cancer (Nilsson
et al., 2014), and T cell activation (Ron-Harel et al., 2016) but(D) Functional enrichment within all proteins upregulated >2-fold with p < 0.075 4
proteins. Overall, 41 clusters were significantly enriched (Table S2). For the pur
terms, where available for individual clusters that had been identified using U
condensation,’’ and ‘‘Kinesin, motor domain’’ were concatenated into ‘‘Cell cycle
(E) Heatmap of averaged relative abundances of glycolytic pathway component
(F) LC-MS analysis of media glucose consumption and lactate production from c
mean ± SEM decrease in media glucose and 24-h increase in media lactate are
(G) Growth curves of newly infected primary human B cells grown in complete me
**p < 0.01 (paired one-tailed t test).
See also Figures S1–S3 and Tables S1 and S2.has not previously been studied in the context of viral oncogen-
esis or in primary human B cell activation.
RESULTS
EBV Upregulation of Human B Cell Metabolic Pathways
To identify virus-inducedmetabolic pathways important for EBV-
driven B cell growth, we used 10-plex TMT andMS3mass spec-
trometry to analyze primary human CD19+ B cells either left
uninfected or infected at a low multiplicity with the B95-8 strain
of EBV, which was originally isolated from a patient with IM. Suc-
cessfully infected B cells were isolated by flow cytometry at nine
time points after initial infection using CD23 plasma membrane
(PM) expression as a proxy for infection (Wang et al., 1987; Thor-
ley-Lawson and Mann, 1985). Three whole-cell lysate (WCL)
biological replicates, each comprising cells pooled from four
distinct human donors, were performed (Figure 1A). We addi-
tionally quantified changes in PM protein expression for one
replicate. Immunoblots demonstrated the expected pattern of
EBV oncoprotein expression (Figure 1B).
We quantified 8,054 B cell and 29 EBV-encoded proteins in at
least one replicate. Across all three replicates, 6,455 B cell and
11 EBV-encoded proteins (Figures 1C and S1A) were quantified;
data exhibited strong concordance across replicates (Figures
S1B and S1C). All data are shown in Table S1, where the work-
sheet ‘‘Plots’’ is interactive and allows generation of temporal
graphs ofWCL and PM expression of any of the identified human
and viral proteins. Throughout this manuscript, all analyses are
based on the average values from all analyzed replicates.
Six clusters of B cell proteins with distinct temporal expression
patterns over the transformation time course were identified by
way of k-means analysis (Figures 1C and S1D). We used Data-
base for Annotation, Visualization, and Integrated Discovery
(DAVID) software (Huang da et al., 2009a, 2009b) to identify path-
ways enriched among significantly upregulated proteins (clus-
ters I–III) at 4 days post-infection (DPI) and identified multiple
metabolic terms including 1C metabolism and serine biosyn-
thesis (Figure 1D). Among quantified viral proteins, particularly
high EBNA2 expression was observed 2 DPI, which correlated
with markedly elevated levels of MYC, a well-known master
regulator of cellular metabolism (Figures S2A and S2B). We
also discovered two new EBV open reading frames, whose ex-
pressed gene products increased late in infection (Figures
S2A, S2C, and S2D). Approximately 20 EBV lytic cycle proteins
were also quantified, including several metabolic enzymes (Fig-
ure S2A). This likely represents leaky lytic protein expression
rather than true lytic replication, as we were able to detect 72
EBV proteins in our similar TMT analysis of the EBV B cell lytic
cycle (Ersing et al., 2017). Alternatively, it might have been duedays post-EBV infection (clusters I–III) against a background of all quantified
poses of simplified display, these were concatenated into hierarchical parent
niprot or Gene Ontology. For example, ‘‘Sister chromatid cohesion,’’ ‘‘DNA
.’’
enzymes at each indicated time point.
ultures of primary B cells at the indicated time points post-infection. The 24-h
shown at the indicated DPI, n = 3. *p < 0.05 (paired one-tailed t test).
dia containing either glucose or galactose. Data show the mean ± SEM, n = 3.
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Figure 2. EBV Induces Mitochondrial One-Carbon Metabolism in Newly Infected B Cells
(A) Functional enrichment of mitochondrial pathwaysmost highly induced by primary human B cell upon EBV infection. Enrichment was examined in the subset of
proteins upregulated by at least >2-fold, atR1 time point, in comparison to all quantified mitochondrial proteins. Representative terms are shown, and full details
of enriched terms are shown in Table S3.
(B) Fold change in expression of select metabolic enzymes at 2 DPI relative to resting B cells. Data show the mean + SD, n = 3.
(C) Temporal plots of relative abundances of the indicated mitochondrial one-carbon enzymes at the indicated DPI. Data show the mean ± SEM, n = 3.
(D) Immunoblot analysis of SHMT2, MTHFD2, or load-control DDX1 expression in primary human B cells at the indicated DPI. Representative of n = 3.
(E) Immunoblot analysis of SHMT2, MTHFD2, MTHFD1L, or DDX1 expression in uninfected cells or cells equally infected with either P3HR-1, UV-inactivated
B95-8, or B95-8 virus 4 DPI. n = 2.
(legend continued on next page)
542 Cell Metabolism 30, 539–555, September 3, 2019
to full or abortive lytic replication in a small population of cells.
However, flow cytometric analysis at 4 DPI identified that most
cells were negative for gp350, indicating that lytic reactivation
was unlikely to be the driver of the metabolic changes (Figures
S2E and S2F). Profiling of 712 PM proteins revealed widespread
EBV-driven remodeling of the PM proteome, particularly amino
acid and ion transporters, coinciding with the onset of B cell
hyperproliferation (Figures S3A–S3C).
Early Induction of Aerobic Glycolysis in Newly Infected
B cells
EBV induces aerobic glycolysis in infected B cells, but how early
this occurs in B cell transformation remains undefined
(McFadden et al., 2016; Darekar et al., 2012; Sommermann
et al., 2011). Early upregulation of all glycolytic enzymes was de-
tected, with the rate-limiting enzyme hexokinase 2 (HK2) highly
induced by 2 DPI (Figure 1E). Thioredoxin-interacting protein
(TXNIP), a potent negative regulator of glucose metabolism (Par-
ikh et al., 2007), was concomitantly and strongly downregulated
by EBV (Figure 1E). PM proteomic data and subsequent valida-
tion by flow cytometry suggested that EBV infection induced
substantial re-localization of GLUT1 to the PM (Figure S3D).
Consistent with GLUT1 trafficking to the PM and subsequent
enhanced glycolytic flux, B cell glucose consumption and lactate
release were increased by 2 DPI and were maximal at 4 DPI (Fig-
ures 1F and S3E). EBV-driven outgrowth was strongly impaired
when cells were cultured in media containing galactose instead
of glucose (Figure 1G), highlighting glucose as a key carbon
source in viral B cell transformation. As EBNA2 is the major
EBV transcription factor expressed at this early time point, we
determined whether it was necessary for EBV-driven aerobic
glycolysis. Wemade use of the 2-2-3 EBNA2-HT B cell line (here-
after referred to as EBNA2-HT), where 4-hydroxytamoxifen (4HT)
positively regulates nuclear localization and stability of a condi-
tional EBNA2 allele, comprising EBNA2 fused to a mutant
estrogen-receptor-ligand-binding domain (Zhao et al., 2006;
Schuhmacher et al., 2001). Conditional inactivation of EBNA2-
HT by 4HT withdrawal strongly impaired LCL lactate release
(Figure S3F), further suggesting an important role for EBNA2 in
stimulating glycolysis.
EBV Triggers Extensive Mitochondrial Remodeling in
Newly Infected B Cells
Relatively little is known about EBV-mediated reprogramming of
the mitochondrion. Using the MitoCarta 2.0 database (Calvo
et al., 2016), 799 B cell mitochondrial proteins were identified
by our temporal profiling. Mitochondrial proteome remodeling
commenced shortly after infection and even prior to mitosis,
which is suggestive of an important role in viral B cell growth(F) ChIP-seq tracks of the indicated transcription factors or the activating histone
Shown also are GM12878 ChIA-PET-defined long-range DNA linkages between
(G) Quantitative PCR analysis ofMTHFD2 transcript expression in EBNA2-HT cel
for growth) of 4HT (1 mM) for 48 h. Data show the mean + SEM, n = 3. ***p < 0.0
(H) Immunoblot analysis of MTHFD2, MYC, and tubulin expression in EBNA2-HT c
(I) Immunoblot analysis of MTHFD2, MYC, and tubulin expression in P493-6 cell
(J) Immunoblot analysis of MYC, MTHFD2, and GAPDH expression in Cas9+ GM
MYC-targeting sgRNAs. n = 2.
See also Figure S4 and S5 and Table S3.transformation (Figures 1D, 2A, and S4A–S4C). Notably, since
mostmitochondrial proteins are encoded by the host cell nuclear
genome, EBV nuclear antigens can regulate their expression.
EBV upregulated 35 of the 98 quantified nuclear genome-
encoded electron transport chain (ETC) components (Fig-
ure S4B) by R1.5-fold at Rone time point, including two ETC
components encoded by the mitochondrial genome, MT-ATP6
and MT-ATP8. We observed enhanced basal and maximal oxy-
gen consumption rates (OCRs) in newly infected cells (Fig-
ure S4D), suggesting that increased oxidative capacity might
be important for successful outgrowth. Newly infected cells
were treated with either piericidin A, a complex I inhibitor, or anti-
mycin, a complex III inhibitor. Each significantly diminished
EBV-driven B cell outgrowth (Figure S4E). Thus, the concurrent
induction of the Warburg effect and the upregulation of oxidative
phosphorylation are each important for supporting outgrowth of
B cells undergoing viral transformation.
DAVID analysis identified ribosome biogenesis and 1C meta-
bolism as themost strongly upregulatedmitochondrial pathways
in newly infected B cells (Figures 2A and 2B). Mitochondrial 1C
metabolism uses serine as a precursor for 1C unit, NAD(P)H,
ATP and glycine generation. EBV robustly upregulated mito-
chondrial 1C enzymes by 2 DPI (Figures 2A–2D), whereas rela-
tive abundances of cytoplasmic 1C, mitochondrial fatty acid
oxidation, and tricarboxylic acid cycle (TCA) proteins showed lit-
tle change (Figure 2B). EBV also upregulated the mitochondrial
folate transporter SLC25A32 (Figure S4A), dihydrofolate reduc-
tase (DHFR) (Figure 2B), which is responsible for generating
the 1C carrier tetrahydrofolate (THF) and is a target of the antifo-
late drug methotrexate, and the recently identified mitochondrial
serine transporter SFXN1 (Kory et al., 2018) (Table S1). Notably,
EBV upregulated MTHFD2, a mitochondrial enzyme not ex-
pressed by resting B cells or by most adult cells but among
the most highly induced metabolic enzyme in human cancer
(Nilsson et al., 2014). Collectively, these data suggest that EBV
remodels B cell mitochondria to support the substantial physio-
logical shift from quiescence to rapid lymphoblastic proliferation.EBNA2 Upregulates Mitochondrial 1C Metabolism
ATF4 is the major mitochondrial 1C gene transcription activator
(Ben-Sahra et al., 2016; Bao et al., 2016). Although ATF4 is tran-
scribed in LCLs (Arvey et al., 2012), ATF4 protein was not de-
tected by proteomics or by immunoblot. In support of this result,
we validated the ATF4 antibody by showing that LCL ATF4
immunoblot signal could be induced by tunicamycin treatment
and that this signal could be suppressed by CRISPR ATF4 tar-
geting. Notably, neither tunicamycin-mediated ATF4 induction
nor CRISPR-mediated ATF4 depletion altered LCL MTHFD2
levels (Figure S5A). Likewise, leaky EBV lytic gene expressionepigenetic marks H3K27Ac or H3K4Me3 at the GM12878 LCLMTHFD2 locus.
an upstream MOB1A locus enhancer and MTHFD2.
ls cultured in the presence (permissive for growth) or absence (non-permissive
05 (one-sample t test).
ells cultured in the presence or absence of 4HT (1 mM). Representative of n = 3.
s cultured with the indicated supplement. Representative of n = 3.
12878 LCLs following the expression of non-targeting control or independent
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was unlikely to drive 1C induction since our prior proteomic anal-
ysis of B cell EBV lytic reactivation (Ersing et al., 2017) did not
demonstrate 1C enzyme induction (Figure S5B).
Given the key EBNA2 role in aerobic glycolysis induction, we
hypothesized that EBNA2 might be a viral master regulator of
B cell metabolism and tested its role in mitochondrial 1C induc-
tion. Primary human B cells were equally infected with B95-8 or
the non-transforming P3HR-1 EBV strains (Miller et al., 1974,
1975) (Figures S5C and S5D), using input viral genome copy
number to normalize level of infection. P3HR-1 lacks EBNA2
and most of the EBNA-LP open reading frames (Rowe et al.,
1985; Rymo et al., 1985; Tsang et al., 1991; Wang et al., 1990).
B95-8, but not P3HR-1 or UV-irradiated B95-8, could induce
the expression of mitochondrial 1C enzymes at 4 DPI (Figure 2E)
despite equivalent infection levels, as evaluated by post-infec-
tion viral genome copy number assay and EBNA1 confocal
immunofluorescence analysis. These data suggest that expres-
sion of EBV-encoded EBNA2 and/or EBNA-LP, rather than an
innate immune response to the viral particle, is required for the
induction of mitochondrial 1C metabolism.
To further investigate possible EBNA2 roles in MTHFD2 induc-
tion, we used publicly available LCL chromatin immunoprecipita-
tion with deep sequencing (ChIP-seq) (ENCODE Project
Consortium, 2012; Wood et al., 2016; Zhao et al., 2011) and
chromatin interaction analysis by paired-end tag (ChIA-PET)
data (Jiang et al., 2017) to identify transcription factor occu-
pancy. EBNA2 and its cofactor RBP-Jkwere found to co-occupy
theMTHFD2 promoter, as well as upstream intragenic and inter-
genic enhancers that loop to the MTHFD2 promoter (Figure 2F).
Inactivation of the conditional EBNA2 allele resulted in rapid loss
of MTHFD2 transcript and protein (Figures 2G and 2H).
EBNA2 highly upregulates MYC (Kaiser et al., 1999; Zhou
et al., 2015), and both proteins can act synergistically to induce
EBV targets. As expected, conditional EBNA2 inactivation
caused rapid downregulation of MYC levels (Figure 2H). Since
MYCandMAXco-occupy the LCLMTHFD2 promoter (Figure 2F)
and given MYC’s role in MTHFD2 regulation in acute myeloge-
nous leukemia (Pikman et al., 2016), we investigated a potential
role for MYC in EBV induction of MTHFD2 expression. With
the P493-6 B cell line, an LCL that expresses a conditional
4HT-responsive EBNA2 allele and also carries a heterologous
MYC allele controlled by a Tet-OFF promoter (Schuhmacher
et al., 2001), we found that re-expression of MYC was sufficient
to restore MTHFD2 expression upon EBNA2 inactivation by 4HT
withdrawal (Figure 2I) and observed that MTHFD2 and MYC
levels were closely correlated. Cas9 editing of MYC directed
by either of two distinct single-guide RNAs (sgRNAs) caused
loss of MYC protein and a concomitant decrease in MTHFD2
protein abundance prior to LCL cell death (Figure 2J). Taken
together, these results identify EBNA2 as the first viral oncopro-
tein important for mitochondrial 1C metabolism induction by a
mechanism that involves MYC instead of ATF4.
EBNA2 and MYC Upregulate B Cell Import and
Mitochondrial 1C Catabolism of Serine
Serine and glycine fuel mitochondrial 1C metabolism (Ducker
and Rabinowitz, 2017; Yang and Vousden, 2016). We hypothe-
sized that newly infected cells might therefore increase uptake
and/or de novo synthesis of serine or glycine. Media liquid chro-544 Cell Metabolism 30, 539–555, September 3, 2019matography-mass spectromtry (LC-MS) analysis revealed avid
consumption of serine but not glycine over the first week after
EBV infection, which peaked at 4 DPI, coinciding with the onset
of BL-like hyperproliferation and maximal MYC abundance (Fig-
ures 3A and S5E). Consistent with this observation, EBV mark-
edly upregulated whole cell and PM levels of the major serine
transporters SLC1A4 (ASCT1) and SLC1A5 (ASCT2) by 4 DPI
(Figures 3B and S5F). In contrast, neither EBNA2-deficient
P3HR-1 nor UV-irradiated B95-8 EBV robustly upregulated
ASCT2 (Figure 3C).
Serine and glycine are non-essential amino acids but are often
important for transformed cell growth (Locasale et al., 2011; Pos-
semato et al., 2011). To test whether EBV infection renders pri-
mary B cells auxotrophic for serine and/or glycine, we performed
growth transformation assays in either replete media or media
deficient for serine and/or glycine. Interestingly, while glycine
withdrawal had little effect, exogenous serine depletion signifi-
cantly impaired EBV-driven primary B cell outgrowth (Figure 3D).
The lack of effect with glycine withdrawal was consistent with the
notion that serine catabolism generates sufficient intracellular
glycine (Ducker et al., 2017). These results support a model
where EBNA2 upregulates import of exogenous serine to enable
B cell metabolic remodeling and hyperproliferation.
Imported serine can be catabolized by either the cytosolic or
mitochondrial 1C pathways. To identify the 1C compartment
activated by EBV infection, we performed isotope tracing exper-
iments on newly infected primary human B cells grown in the
presence of [2,3,3-2H]-serine. The cytosolic pathway results in
the stable incorporation of two deuterons into deoxythymidylate
triphosphate (M+2 labeling of dTTP), whereas mitochondrial 1C
results in the production of M+1-labeled dTTP (Figure 3E).
Isotope tracing identified M+1 dTTP as the predominant species
(Figure 3F), indicating that EBV activatesmitochondrial 1Cmeta-
bolism in newly infected cells and that a major reason that EBV
upregulates the import of exogenous serine is to support mito-
chondrial 1C metabolism.
EBNA2 and MYC Upregulate De Novo Synthesis of the
1C Fuel Serine
In addition to EBV’s effects on serine import, temporal proteomic
analysis also highlighted EBV upregulation of the de novo serine
synthesis (DNSS) pathway, which converts the glycolytic inter-
mediate 3-phosphoglycerate (3-PG) into serine (Figure S5G).
All DNSS enzymes were strongly induced by EBV by 4 DPI (Fig-
ures S6A and S6B). Given the finding that EBV infection induces
serine auxotrophy, we next tested whether DNSS was also
important for infected cell growth. Newly infected cells and
GM12878 LCLs were treated with either DMSO or with one of
two structurally distinct PHGDH inhibitors, CBR-5884 (Mullarky
et al., 2016a, 2016b) or NCT-503 (Pacold et al., 2016b, 2016a).
PHGDH inhibition by either antagonist significantly diminished
B cell proliferation (Figures S6C and S6D).
To investigate EBV’s effects on serine flux, isotope tracingwith
U13C-glucose was performed with resting and newly infected
B cells (Figure S6E). M+3 labeled serine was detected in newly
infected cells, while resting cells showed no detectable signal,
suggesting increased DNSS from U13C-glucose-derived 3-PG
and consistent with the notion that EBV activates DNSS flux (Fig-
ure S6F). Treatment of newly infected cells with either CBR-5884
Figure 3. EBV Infection Induces B Cell Serine Transporter Expression, Uptake, and Catabolism
(A) LC-MSmeasurements of media serine concentrations of primary B cells cultured at the indicated DPI. Values indicate mean + SEM serine consumption over a
24-h period at the indicated time point, n = 3. *p < 0.05 (paired two-tailed t test).
(B) Temporal plots of PM relative abundances of the neutral amino acid transporters ASCT1 and ASCT2.
(C) Flow cytometry of ASCT2 in uninfected B cells maintained in culture for 4 days or at 4 DPI with the indicated EBV strain at equal levels of infection.
Representative of n = 3.
(D) Growth curves of newly infected primary B cells cultured in either replete media or media lacking serine, glycine or both serine and glycine. Data show the
mean ± SEM, n = 3. *p < 0.05; **p < 0.01 (paired one-tailed t test).
(E) Schematic illustrating the fate of [2,3,3-2H]-serine in either the cytosolic (purple) or mitochondrial (red) one-carbon metabolic pathway. Enzymes involved in
catabolizing serine are indicated in blue bold font.
(F) LC-MS measurements of dTTP isotopologues from 0 and 4 DPI cells grown in the presence of [2,3,3-2H]-serine. Data show the mean with SEM, n = 3.
See also Figures S5 and S6.or NCT-503 resulted in significant decreases in cellular and me-
dia M+3 serine levels, indicative of the inhibitors’ on-target ef-
fects (Figure S6F). Cellular M+3 serine abundance was relatively
low (1%) in newly infected cells grown under replete condi-
tions, perhaps because DNSS-derived serine may be rapidly
consumed. However, when serine was excluded from the media
and formate was supplemented, the proportion of M+3 serine
increased to nearly 15% (Figure 6G). This finding is consistent
with the hypothesis that DNSS may serve to augment intracel-
lular serine pools under conditions of limiting extracellular serine,
as might happen in vivo.
Further supporting the role of EBNA2 as a viral master regu-
lator of B cell metabolism, its conditional inactivation of EBNA2
in the EBNA2-HT cell line impaired PHGDH mRNA expression
(Figure S6H). In addition, conditional MYC expression in
P493-6 B cells grown under EBNA2-non-permissive conditions
was sufficient to upregulate mRNAs encoding 1C and DNSS en-
zymes (Figure S6I) (Lin et al., 2012). Collectively, our data sug-
gest that EBNA2- andMYC-induced serine uptake and synthesis
are important determinants of EBV-infected B cell proliferation.Serine Catabolism and Mitochondrial 1C are Critical for
EBV-Infected B Cell Growth
To test whether EBV-induced 1C metabolism was important for
transforming B cell outgrowth, newly infected primary B cells
were treated with one of two chemically distinct 1C pathway in-
hibitors. SHIN1 selectively blocks cytosolic SHMT1 and
mitochondrial SHMT2 (Ducker et al., 2017), while MTH-1479 is
a specific MTHFD2 antagonist (Chandrasekaran et al., 2017).
Inhibition of either SHMT1/2 or MTHFD2 significantly diminished
EBV-driven primary B cell proliferation (Figures 4A and 4B). We
confirmed the on-target effects of SHIN1 and MTH-1479 by
LC-MS analysis of dTTP from cells fed [2,3,3-2H]-serine and
treated with either inhibitor. As expected for on-target effects,
SHIN1 treatment resulted in the loss of M+1-labeled dTTP and
an increase in the unlabeled M+0 population, while MTH-1479
treatment caused a decrease in M+1 dTTP with a concomitant,
large increase in the M+2 isotopologue, consistent with reversal
of 1C flux (Figure 4C).
To further assess 1C roles in EBV-driven proliferation and sur-
vival, we treated newly infected primary B cells and GM12878Cell Metabolism 30, 539–555, September 3, 2019 545
Figure 4. One-Carbon Metabolism Is Crucial for Efficient EBV-Infected Cell Growth and Survival
(A) Growth curves of newly infected primary B cells treated with DMSO or SHIN1 (10 mM). Data show the mean ± SEM, n = 4. **p < 0.01 (paired one-tailed t test).
(B) Growth curves of newly infected B primary cells treated with DMSO or MTH-1479 (10 mM). Data show the mean ± SEM, n = 7. ***p < 0.005 (paired one-tailed
t test).
(C) LC-MS measurements of dTTP isotopologues from 4 DPI cells treated for 24 h with either DMSO, SHIN1 (10 mM) or MTH-1479 (10 mM), and grown in the
presence of [2,3,3-2H]-serine. Data show the mean with SEM, n = 3.
(D) CFSE dye dilution assays of newly infected primary B cells and LCLs treated with either DMSO or SHIN1 (10 mM). Cells were stained with CFSE at 4 DPI and
immediately treated with either DMSO or SHIN1. Data shown are representative of n = 3.
(legend continued on next page)
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LCL with SHIN1 and performed carboxyfluorescein diacetate
succinimidyl ester (CFSE) dye dilution and 7-aminoactinomycin
D (7-AAD) viability assays. SHIN1 decreased proliferation and
increased cell death of both newly infected B cells and fully
transformed GM12878 LCLs (Figures 4D and S7A). To exclude
the possibility that these proliferative defects were due to off-
target effects of SHIN1, we attempted to rescue SHIN1-treated
cells with formate supplementation. Addition of millimolar levels
of formate to the culture media rescued the growth of newly in-
fected cells; addition of excess glycine did not promote further
growth (Figure S7B). Furthermore, SHIN1 negatively impacted
outgrowth of primary human B cells in an in vitro transformation
assay (Figure S7C). To further investigate EBV-induced mito-
chondrial 1C roles in lymphoblastoid B cell growth and survival,
Cas9-expressing GM12878 LCLs were transduced with lenti-
virus expressing non-targeting control or an MTHFD2 targeting
sgRNA. MTHFD2 knockout (KO) by either of two independent
sgRNAs significantly diminished LCL proliferation (Figure S7D)
and caused accumulation of cells at theG1/S phase (Figure S7E).
Stable expression of a Cas9-resistant silent point mutant
MTHFD2 cDNA (MTHFD2R) restored cell proliferation in
MTHFD2 KO LCLs (Figures 4E and 4F), confirming the role of
MTHFD2 in promoting LCL growth and survival.
EBV mimics physiological signals to drive germinal center
B cell growth and survival. We hypothesized that 1Cmetabolism
was likewise activated by prototypical agonists operative in
germinal center reactions. RNA sequencing (RNA-seq) analysis
of resting versus recombinant CD40 ligand (CD40L)-stimulated
primary human B cells revealed robust upregulation of mito-
chondrial 1C enzymes within 24 h post-stimulation that was sus-
tained at 96 h post-stimulation (Figures 4G and 4H). Similarly,
stimulation by either B cell receptor cross-linking or Toll-like
receptor 9 agonist CpG, but not by interleukin-4 (IL4), induced
primary B cell MTHFD2 expression (Figure 4H).EBV-Induced Mitochondrial 1C Metabolism Generates
Compartment-Specific NADPH
Proteomic profiling highlighted viral induction of anabolic path-
ways that avidly consume NADPH, including fatty acid and
cholesterol biosyntheses (Figure 1D; Table S1). In addition to
key roles in providing carbon units for anabolic reactions, mito-
chondrial 1C metabolism generates reducing power and sub-
strate-level ATP. While the glucose-derived pentose phosphate
pathway (PPP) shunt is traditionally considered the major
NADPH source, primary B cells do not have robust PPP physi-
ology (Xiao et al., 2018), and EBV downregulated several PPP
enzymes, including the rate-limiting enzyme, glucose-6-phos-
phate dehydrogenase (G6PD) (Table S1). Yet, despite EBV in-
duction of NADPH-consuming pathways, we found that EBV
infection significantly increased NADPH/NADP+ ratios in newly(E) Growth curve analysis of Cas9+ GM12878 LCL following expression of the in
MTHFD2-targeting sgRNAs. ***p < 0.005 (paired one-tailed t test).
(F) Immunoblot analysis of WCL from Cas9+ GM12878 LCL following expressio
control or MTHFD2-targeting sgRNAs. Representative blot of n = 3 replicates sh
(G) Normalized RNA-seq counts of the indicated mRNAs encoding 1C enzymes in
times. *p < 0.05; **p < 0.01; ***p < 0.005 (unpaired two-tailed t test).
(H) Immunoblot analysis of WCL from primary human B cells stimulated as indic
See also Figure S7.infected B cells, with little effect on NADH/NAD+ ratios out to 7
DPI (Figures 5A and 5B). These results suggest that EBV induces
NADPH production, likely through a non-PPP mechanism.
We hypothesized that EBV may utilize mitochondrial 1C as an
important NAPDH source. To experimentally determine whether
EBV induces NADPH production throughmitochondrial 1C path-
ways, we performed [2,3,3-2H]-serine labeling experiments with
newly infected cells (Figure 5C). [2,3,3-2H]-serine catabolism
yields 2H-containing 10-formyl-THF, which contributes to deute-
rium labeling of the adenine backbone of NADP(H) cofactors, as
well as redox-active hydrides. Compared to the NADP+ labeling
pattern, NADPH displayed a shift toward the heavy M+3 and
M+4 isotopologues, suggesting that the redox-active hydrogen
atoms are derived from exogenous serine through 1C meta-
bolism over the timescale (4 h) of this labeling experiment. 1C
blockade by SHIN1 diminished M+3 and M+4 labeling, support-
ing the idea that 1C metabolism is a crucial means of generating
reducing power in the form of NADPH.
To gain insights into compartment-specific NADPH roles in the
proliferation of fully transformed LCLs, we utilized the genetically
encoded NADPH oxidase triphosphopyridine nucleotide oxi-
dase (TPNOX), which can be expressed as cytosolic or mito-
chondrial probes (Cracan et al., 2017; Titov et al., 2016). While
expression of cytosolic TPNOX had little effect on LCL prolifera-
tion, mitochondrial TPNOX significantly diminished LCL growth
(Figure 5F), indicating an important intra-mitochondrial NADPH
role. In contrast, expression of either TPNOX isoform had little ef-
fect on HeLa cell growth (Cracan et al., 2017). Furthermore, the
LCL NADPH/NADP+ ratio was significantly diminished by
MTHFD2 KO and restored by MTHFD2R cDNA rescue (Fig-
ure 5G). Conditional EBNA2 inactivation significantly reduced
LCL NADPH/NADP+ ratio while also inducing a small but signif-
icant increase in the NADH/NAD+ ratio (Figure S7F), indicating
that EBV-induced MTHFD2 has a key role in producing intra-
mitochondrial NADPH in support of EBV-transformed B cell
growth.Serine-Derived Formate Fuels Infected B Cell
Nucleotide Synthesis
EBV triggers B cell transition from quiescence to hyperprolifera-
tion, greatly increasing the need for de novo nucleotide synthe-
sis. We hypothesized that a major role for EBV-induced 1C
metabolism is to provide 1C units and/or glycine for nucleotide
synthesis. We therefore tested the extent to which formate sup-
plementation could rescue the outgrowth of EBV-infected cells
in serine-deficient media. Exogenous serine withdrawal effects
on EBV-driven cell proliferation could be significantly rescued
by the 1C donor formate (Figure 6A), suggesting that 1C is a
major source of carbon units for nucleotide synthesis in newly in-
fected B cells. Addition of glycine together with formate did notdicated GFP control or MTHFD2R rescue cDNAs and the indicated control or
n of the indicated GFP control or MTHFD2R rescue cDNAs and the indicated
own.
primary human B cells stimulated byMEGACD40L (50 ng/mL) for the indicated
ated. Representative of n = 2.
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Figure 5. Mitochondrial 1C-derived NADPH Is an EBV Dependency
Factor
(A) Whole-cell NADPH/NADP+ ratios in primary B cells at the indicated time
points post-EBV infection. Shown are mean ± SEM values from n = 4 repli-
cates. *p < 0.05; **p < 0.01 (one-sample t test).
(B) Whole-cell NADH/NAD+ ratios in primary B cells at the indicated time points
post-EBV infection. Data show the mean ± SEM values from n = 4 replicates.
n.s., not significant (one-sample t test).
(C) LC-MS analysis of NADP+ and NADPH cofactors in primary B cells at 4 DPI
fed [2,3,3-2H]-serine for 4 h in the presence of either DMSO or SHIN1 (10 mM).
Data show the mean with SEM, n = 4. Natural isotope correction was not
performed.
548 Cell Metabolism 30, 539–555, September 3, 2019further enhance proliferation (Figure 6A), perhaps due to intrinsic
B cell deficiencies in glycine uptake (Ducker et al., 2017). Despite
having important roles in nucleotide synthesis, serine withdrawal
did not provoke an overt DNA damage response in newly in-
fected cells, as judged by immunoblot for gH2AX (Figure S7G),
suggesting that nucleotide-imbalance-related genome insta-
bility was not a major cause of growth inhibition. Similarly, serine
withdrawal or 1C blockade by SHIN1 did not reduce mitochon-
drial DNA (mtDNA) or EBV genome copy numbers (Figures
S7H–S7K). MTHFD2 KO also did not diminish the mitochondrial
membrane potential (Figure S7L). These results suggest that
EBV-induced 1Cwas instead necessary for nucleotide synthesis
for other roles, possibly including B cell nuclear genome synthe-
sis and/or RNA transcription.
We hypothesized that serine was required tomeet the bioener-
getic and biosynthetic requirements of newly infected cell
outgrowth. Indeed, exogenous serine withdrawal decreased
newly infected B cell ATP levels, which could be reversed with
formate supplementation (Figure 6B). Mechanistically, serine
deprivation caused the accumulation of de novo purine synthesis
intermediates glycinamide ribonucleotide (GAR) and 5-aminoimi-
dazole-4-carboxamide ribonucleotide (AICAR), which were
completely consumed once cells were supplemented with
formate (Figure 6C). Furthermore, U13C-serine metabolic tracing
readily labeled cellular adenosine monophosphate (AMP) pools,
suggesting an important contribution of de novo purine biosyn-
thesis in supporting adenine nucleotide levels (Figure 6D). Serine
deprivation also diminished newly infected cell basal and
maximal OCRs (Figures 6E and 6F). Consistent with an earlier
report (Maddocks et al., 2016), serine deprivation did not result
in an increase in Thr172 phosphorylation on AMP-activated pro-
tein kinase a (AMPKa) (Figure S7G), likely because AMP, ADP,
and ATP are equally affected by serine deprivation and the ad-
enylate charge is not substantially altered.
Viral Activation of Mitochondrial 1C Generates
Glutathione for Redox and Glycine Toxicity Defense
Marked upregulation of cholesterol and lipid synthetic pathways
during EBV transformation may be necessary for B cell remodel-
ing but likely generates lipid free radicals that can trigger
ferroptosis (Yang and Stockwell, 2016). Furthermore, while mito-
chondrial 1C was recently found to be a key source of B cell lym-
phoma glycine (Ducker et al., 2017), high 1C flux can generate
potentially toxic levels of intracellular glycine, which necessitates
disposal through the glycine cleavage system (GCS) or via efflux
systems. However, we did not observe significant upregulation
of keyGCSenzymes such as glycine decarboxylase over the first
several DPI at time points of maximal mitochondrial 1C enzyme(D) Left: Growth curves of GM12878 LCLs with stable GFP, TPNOX, or
MitoTPNOX expression. Data show the mean ± SEM, n = 3. n.s., not signifi-
cant; ***p < 0.005 (unpaired two-tailed t test). Right: a representative immu-
noblot of whole-cell extracts for FLAG-tagged TPNOX or MitoTPNOX and
tubulin load-control, n = 3.
(E) Quantitation of overall NADH/NAD+ (black) and NADPH/NADP+ (red) ratios
in Cas9+ GM12878 LCLs expressing the indicated control or MTHFD2-
targeting sgRNA as well as the indicatedGFP orMTHFD2R rescue cDNA. Data
show the mean + SEM, n = 3. n.s., not significant; ***p < 0.005 (one-sample
t test).
See also Figure S7.
Figure 6. One-Carbon Metabolism Generates Formate for Nucleotide Synthesis
(A) Growth curves of newly infected primary B cells cultured in either replete media, serine-deficient media, or serine-deficient media with the indicated
supplement (formate ± glycine). Data show the mean ± SEM, n = 7. p < 0.05; ***p < 0.005 (paired two-tailed t test).
(B) Relative ATP levels in primary B cells 7 DPI grown in replete or serine-deficient media, supplemented with formate, as indicated. Data show the mean + SEM,
n = 4. n.s., not significant; *p < 0.05 (one-sample t test).
(C) LC-MS detection of de novo purine synthesis intermediates GAR and AICAR in newly infected primary B cells 4 DPI. Data show the mean with SEM, n = 3.
*p < 0.05; **p < 0.01 (paired two-tailed t test).
(D) LC-MS detection of AMP isotopologues extracted from resting B cells and 4 DPI cells after labeling with U13C-serine for 24 h. Data show the mean with SEM,
n = 5.
(E) Oxygen consumption rates (OCRs) of primary B cells 4 DPI grown in replete or serine-deficient media and subject to flux analysis in the presence of the
indicated ETC inhibitors. Data show the mean ± SEM, n = 4.
(F) Calculatedmetabolic parameters of primary cells 4 DPI grown in replete or serine-deficient media. Shown aremean + SEM, n = 4. n.s., not significant; *p < 0.05
(paired two-tailed t test).
See also Figure S7.induction (Table S1). Yet, glycine release into the media was only
modestly increased at 4 DPI (Figure S5E). These observations
prompted us to investigate if there was a major cellular sink for
serine-derived glycine during early infection.
De novo glutathione synthesis is central to redox defense and
may represent an avenue for glycine disposal without causing
overt cytotoxicity. Blockade of the 1C pathway either by
SHIN1 (Figure 7A) orMTH-1479 (Figure S7M) increased newly in-fected B cell intracellular reactive oxygen species (ROS) levels,
and EBV infection strongly induced synthesis of glutathione (Fig-
ure 7B). We therefore asked if 1C-derived glycine was being uti-
lized for glutathione synthesis. U13C-serine tracing labeled
approximately 50% of cellular glycine and significant fractions
of the intracellular reduced glutathione (GSH) and oxidized gluta-
thione (GSSG) pools (Figures 7C–7E), indicating that serine
catabolism was indeed a major source of glycine in the newlyCell Metabolism 30, 539–555, September 3, 2019 549
Figure 7. Serine-Derived Glycine Is Used for Glutathione Synthesis and Aids in Redox Homeostasis
(A) Flow cytometry of primary B cells 7 DPI treated with either DMSO or SHIN1 (10 mM) and stained with DCFDA for intracellular ROS quantitation. TBHP (100 mM)
was used as a positive control. n = 2.
(B) LC-MS detection of reduced glutathione (GSH) and oxidized glutathione (GSSG) extracted from primary B cells at 0 and 4 DPI. Data show the mean + SEM,
n = 3. *p < 0.05 (paired one-tailed t test).
(C) Schematic showing metabolic tracing of U13C-serine-derived glycine in de novo synthesis of glutathione. Black circles denote heavy 13C atoms, while white
circles denote light 12C atoms. The reactive thiol bonds are indicated as SH. GSS, glutathione synthase.
(D) LC-MS analysis of glycine abundance in metabolite extracts of resting B cells and 4 DPI cells fed U13C-serine for 24 h. Data show the mean + SEM, n = 4.
(E) LC-MS analysis of GSH and GSSG abundances in metabolite extracts of resting B cells and 4 DPI cells fed U13C-serine for 24 h. Data show the mean + SEM,
n = 4.
(F) Relative viability of primary B cells grown either in replete or serine-deficient media and exposed to the indicated doses of buthionine sulfoximine (BSO) for
3 days from 4 to 7 DPI. Data show themean ± SEMof n = 3 experiments. *p < 0.05; **p < 0.01, ***p < 0.005 (paired one-tailed t test). IC50 valueswere calculated by
non-linear regression analysis.
See also Figure S7.infected cell and that 1C-derived glycine was heavily utilized for
glutathione synthesis. Further, serine withdrawal significantly
increased newly infected B cell sensitivity to buthionine sulfoxi-
mine (BSO), which inhibits the first step of glutathione synthesis,
as evidenced by the 4-fold decrease in the half maximal inhibi-
tory concentration (IC50) levels on cell viability (Figure 7F). These
observations are consistent with the ideas that SHMT2 and
MTHFD2 are key EBV-induced mediators of NADPH and gluta-
thione production and that a significant role exists for mitochon-
drial 1C in newly infected cell redox defense. Taken together,
these results are consistent with the hypothesis that a second550 Cell Metabolism 30, 539–555, September 3, 2019major role for EBV-induced serine catabolism is the provision
of metabolites and reducing power for glutathione synthesis to
mitigate redox stress and possibly also to serve as a sink for
excess glycine produced by 1C metabolism.
DISCUSSION
Humoral immune responses require B cells to rapidly upregulate
metabolic activity in order to support lymphoblast transforma-
tion, growth, and survival. This plasticity is necessary for adap-
tive immune responses, in which B cell clones that successfully
recognize foreign antigens are selected and expanded in lymph
node germinal center reactions. Through expression of a small
number of viral oncoproteins, EBV takes advantage of this
plasticity by mimicking germinal center B cell activation signals.
Viral subversion of host metabolic pathways underlies EBV’s
ability to maintain lifelong carriage and its association with mul-
tiple B cell cancers, particularly in immunosuppressed hosts.
Yet, a systematic analysis of EBV-mediated metabolic reprog-
raming necessary for B cell activation and transformation has
not been performed.
We therefore undertook a near-global scale proteomic analysis
of resting primary human B cells and their transition through
stages of EBV growth transformation. This approach revealed
that EBV targets themitochondrial 1C pathway, beginning shortly
after infection and prior to the first mitosis, a time point where little
information has been available. 1C upregulation was a key factor
in EBV-induced B cell transformation. Our results provide insights
into early events in EBV-mediated metabolic reprograming in
B cell growth transformation and have general implications for
understanding primary B cell activation.
To support 1C induction and other demands of hyperprolifer-
ation, EBV coordinately induced aerobic glycolysis, serine
import, and DNSS within the first 4 DPI by means of EBNA2
and its host target MYC. Thus, EBNA2 is a key oncoprotein
that mediates adaptation of newly infected B cells into a physio-
logic state compatible with rapid cell growth. Notably, we also
found that BL-like overexpression of MYC was also able to
induce mitochondrial 1C. These data suggest that high MYC ac-
tivitymay support germinal-center-dark-zone B cell expansion in
humoral responses. EBNA2 also induces EBV oncoproteins,
including the CD40 mimic LMP1, which may also serve to sup-
port 1C induction in the lymphoblastoid phase time points where
EBNA2 and MYC abundances have decreased.
EBV-induced mitochondrial 1C was found to be a major sup-
plier of carbon units for purine, thymidylate, and glutathione
synthesis necessary for rapid B cell growth, particularly during
BL-like hyperproliferation. Similarly, B cell activation by physio-
logical ligands, including CD40L and B cell receptor stimulation,
also upregulatedMTHFD2 expression, suggesting similar impor-
tant roles in physiological B cell humoral responses.
1C metabolism is highly compartmentalized; MTHFD2 abla-
tion was not rescued by reversal of 1C flux through the cytosolic
pathway (Scotti et al., 2013), highlighting non-redundancy be-
tween the cytosolic and mitochondrial 1C pathways. In contrast
to SHMT2 inactivation in primary murine T cells, which could be
rescued by formate and the anti-oxidant N-acetyl-cysteine
(NAC) (Ron-Harel et al., 2016), we were unable to fully rescue
serine deprivation with this combination (data unpublished).
Our TPNOX andCRISPR results suggest that generation of intra-
mitochondrial NADPH is a secondmajor role of 1Cmetabolism in
EBV B cell growth transformation. While we cannot exclude that
oxygen consumption by mitoTPNOX could have contributed to
the observed LCL growth defects, comparable cytosolic TPNOX
expression did not cause growth deficit. Likewise, expression of
either TPNOX isoform had little effect on HeLa cell growth (Cra-
can et al., 2017). In contrast to activated primary T cells, serine
withdrawal also did not produce overtly deleterious effects on
mtDNA replication or cause DNA damage checkpoint activation,
suggesting that mitochondrial 1C metabolism may have uniquefunctions in B cell physiology and EBV pathobiology. Additional
roles in substrate-level ATP generation remain plausible.
MTHFD2may boost flux through B cell mitochondrial 1C path-
ways, as occurs during early embryogenesis (Shin et al., 2014,
2017). Although the isozyme MTHFD2L has key roles in later
embryogenesis and in adult tissues, we did not detect its expres-
sion in B cells. B cells have been reported to exhibit constitutively
low PPP activity, with glucose carbon utilization skewed toward
glycolysis (Xiao et al., 2018). Intriguingly, while the phosphatase
PP2A was found to redirect glucose carbon units to PPP in
DLBCLs, we found PP2A catalytic subunit PPP2CA expression
to be unchanged by EBV infection, and EBV suppressed G6PD
expression by nearly 2-fold. Furthermore, LCLs can be estab-
lished from G6PD-deficient human B cell donors (Maeda
et al., 1992). Taken together with the finding that MTHFD2
ablation reduced LCL NADPH/NADP+ ratios, our results suggest
that EBV may induce mitochondrial 1C metabolism in lieu of
increasing PPP flux to provide NADPH for B cell transformation,
with possible roles in redox defense and anabolic growth.
MTHFD2 has been reported to be a major contributor to cellular
NADPH in HEK293 cells (Fan et al., 2014) but not previously
implicated in primary cell or B cell NADPH generation.
Temporal proteomic analysis revealed that EBV significantly
upregulates fatty acid and cholesterol synthesis pathways. Lipid
peroxides can be a major source of free radicals that may trigger
ferroptosis in the absence of sufficient NADPH and glutathione.
Our recent CRISPR analysis of EBV-transformed B cell depen-
dency factors (Ma et al., 2017) found that LCLs are exquisitely
dependent on the key glutathione-dependent ferroptosis regu-
lator glutathione peroxidase 4 (GPX4). While resting B cells did
not appreciably produce glutathione, EBV infection robustly
upregulated serine-dependent glutathione production.
Although EBV robustly induces aerobic glycolysis, we found
that an intact ETC was crucial for efficient EBV-induced transfor-
mation. While ETC integrity is primarily linked to OXPHOS-
dependent ATP generation, interaction with mitochondrial 1C
metabolism may also underpin its importance in sustaining prolif-
erative cell growth. Consistent with this hypothesis, SHMT2 inhi-
bition causes impaired mitochondrial translation and defective
OXPHOS (Morscher et al., 2018), and ETC dysfunction causes al-
terations in 1C metabolism, with diminished serine-derived
formate production (Bao et al., 2016; Meiser et al., 2016).
Epigenetic silencing plays key roles in EBVB cell growth trans-
formation. Hypermethylation silences host tumor suppressors
and viral lytic genes (Saha et al., 2015). Serine-dependent de
novo ATP synthesis can have a key role in maintaining nucleic
acid methylation marks (Maddocks et al., 2016; Stover et al.,
2018). It is plausible that newly infected B cells catabolize serine
to generate ATP to support methylation of tumor suppressor
genes and viral genome CpG islands (Kalla et al., 2010, 2012).
However, under conditions used in this study, where the methyl
donors methionine and vitamins B6 and B12 were present in cul-
ture, serine is likely not required for DNA and histone methyl-
ation. Nonetheless, as a secondary methyl donor, serine levels
may become significant in vivo, such as in lymphoid germinal
center reactions, where localized depletion of primary methyl
group donors could occur.
Methotrexate inhibits DHFR and is a cornerstone of antifolate
therapies used to target neoplastic and autoimmune B cellCell Metabolism 30, 539–555, September 3, 2019 551
conditions. Denis Burkitt and colleagues reported the use of
methotrexate as a chemotherapeutic agent to treat endemic
BL (Oettgen et al., 1963). Yet, methotrexate and other antifolates
in clinical use are limited by toxicities, including effects on rapidly
growing gastrointestinal tract epithelia. Folate-dependent mito-
chondrial 1C metabolism pathway components, specifically
MTHFD2, may therefore be attractive targets in the therapeutic
treatment of EBV-driven B cell malignancies, given the narrower
range of cells that constitutively express this enzyme.
Limitations of Study
In summary, temporal proteomic profiling provided new insights
into metabolic reprograming in EBV-mediated B cell growth
transformation and highlighted mitochondrial 1C induction as a
key oncogenic event. Our findings underscore mitochondrial
1Cmetabolism as a critical source of 1C units for purine and thy-
midylate synthesis, as a means of producing reducing power in
the form of NADPH and as a pathway for generating glycine for
glutathione synthesis. A key caveat is that we used primary hu-
man B cells derived from peripheral blood and infected by EBV
in vitro. It remains possible that differences in metabolic remod-
eling exist when EBV infects B cells of distinct differentiation
states or in particular in vivo niches. We anticipate that the use
of additional experimental models, including xenograft, human-
ized mice, and organoid systems, together with analyses of
primary human tumor samples, could provide additional future
insights into EBV-driven metabolic remodeling and into the ther-
apeutic potential of 1C pathway blockade. Secondly, although
the EBV B95-8 strain efficiently transforms human B cells, a
genetic deletion removes certain virus-encoded microRNAs
(miRNAs). It is unclear whether these EBV miRNAs may affect
1C metabolism. Thirdly, B95-8 and other type I EBV strains
transform B cells more efficiently than type II EBV strains due
to sequence differences in EBNA2 (Tzellos et al., 2014). It re-
mains to be determined how polymorphisms in EBNA2 and in
other viral genes affect remodeling of B cell metabolism by
type II strains.
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Rabbit anti-MTHFD1L Cell Signaling Cat#14998 RRID:AB_2798680
Rabbit ant-DDX1 Bethyl Laboratories Cat#A300-521A
RRID:AB_451046
Rabbit anti-c-MYC (N-262) Santa Cruz Cat#sc-764
RRID:AB_631276
Rabbit anti-FLAG (DYKDDDDK) Cell Signaling Cat#2368S
RRID:AB_2217020
Mouse anti-a-tubulin (DM1A) Abcam Cat#ab7291
RRID:AB_2241126
Mouse anti-GAPDH (6C5) Abcam Cat#ab8245
RRID:AB_2107448
Rabbit anti-ASCT2 (D7C12) Cell Signaling Cat#8057
RRID:AB_10891440
Rabbit anti-phospho-AMPKa (Thr172) (40H9) Cell Signaling Cat#2535
RRID:AB_331250
Rat anti-ATF4 (W16016A) Biolegend Cat#693901
RRID:AB_2650719
Goat anti-rabbit IgG (H+L) Alexa Fluor 488 Invitrogen Cat#A-11034
RRID:AB_2576217
Goat anti-mouse IgG (H+L) Cross-Adsorbed
Secondary Antibody, Alexa Fluor 488
Invitrogen Cat#A-11001
RRID:AB_2534069
(Continued on next page)
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Goat F(ab’)2 Anti-Human IgM Southern Biotech Cat#2022-01 RRID:AB_2795610
Mouse anti-human GLUT1 Alexa Fluor 647
(Clone 202915)
BD Biosciences Cat#566580
Bacterial and Virus Strains
B95-8 N/A
P3HR-1 N/A
Chemicals, Peptides, and Recombinant Proteins
Tandem mass tag (TMT) 10-plex isobaric reagents Thermo Fisher Cat# 90110
HPLC water VWR Cat# 23595.328
LC-MS grade acetonitrile Merck Cat# 1.00029.2500
Acetonitrile (LC/MS) Fisher Scientific Cat#A955-1
Methanol (LC/MS) Fisher Scientific Cat#A456-1
Water (LC/MS) Fisher Scientific Cat#W6-4
Ammonium acetate (LC/MS) Sigma Cat#14267
Ammonium hydroxide (LC/MS) Fisher Cat#A470-250
Ammonium carbonate (HPLC) Fluka Cat#74415-250G-F
D-Glucose (U-13C6) Cambridge Isotope Laboratories Cat#CLM-1396-1
L-Serine (2,3,3-D3) Cambridge Isotope Laboratories Cat#DLM-582-0.1
L-Serine (13C3) Cambridge Isotope Laboratories Cat#CLM-1574-H-0.1
Sodium L-lactate (13C3) Cambridge Isotope Laboratories Cat#CLM-1579-0.5
XBridge BEH Amide VanGuard Pre-column, 130Å,
2.5 mm, 2.1 mm X 5 mm, 3/pkg
Waters Cat#186007763
Xbridge BEH amide 2.5 mm, 2.1 mm X 100 mm Waters Cat#186006091
SeQuant ZIC-pHILIC (5mm polymer) PEEK
150 x 2.1 mm
EMD Millipore Cat#150460
Formic acid (LC/MS) Fisher Scientific Cat#A117-50
Complete Protease Inhibitor Cocktail Roche Cat#11836153001
Magic C4 resin (5 mm, 100 A) Michrom Bioresources Cat#PM5/64100/00
GP118 resin (1.8 mm, 120 A) Sepax Technologies N/A
Piericidin A Cayman Chemicals Cat#15379
Tunicamycin, Streptomyces lysosuperficus Sigma-Aldrich Cat#654380
Antimycin A from Streptomyces sp. Sigma-Aldrich Cat#A8674
8M guanidine hydrochloride solution Thermo Fisher Scientific Cat#24115
D-(+)-Galactose Sigma-Aldrich Cat#G5388
(Z)-4-Hydroxytamoxifen Sigma-Aldrich Cat#H7904
Doxycycline hyclate Sigma-Aldrich Cat#D9891
Sodium formate Fisher Scientific Cat#S648-500
Glycine American Bioanalytical Cat#AB00730-05000
L-Buthionine-sulfoximine Sigma-Aldrich Cat#B2515
H2DCFDA (H2-DCF, DCF) Thermo Fisher Scientific Cat#D399
2-NBDG (2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-
yl)Amino)-2-Deoxyglucose)
Thermo Fisher Scientific Cat#N13195
Propidium iodide - 1.0-mg/mL solution in water Thermo Fisher Scientific Cat#P3566
PureLinkRNase A (20 mg/mL) ThermoFisher Scientific Cat#12091021
Hoechst 33258, Pentahydrate (bis-Benzimide) -
FluoroPure Grade
ThermoFisher Scientific Cat#H21491
Prolong Gold Antifade Mountant ThermoFisher Scientific Cat#P36930
JC-1 Dye (Mitochondrial Membrane Potential Probe) ThermoFisher Scientific Cat#T3168
CellTrace CFSE Cell Proliferation Kit ThermoFisher Scientific Cat#C34554
7-AAD (7-Aminoactinomycin D) ThermoFisher Scientific Cat#A1310
(Continued on next page)
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Luperox TBH70X, tert-Butyl hydroperoxide solution Sigma-Aldrich Cat#458139
Carbonyl cyanide m-chlorophenylhydrazone (CCCP) Sigma-Aldrich Cat#C2759
Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone Sigma-Aldrich Cat#C2920
Oligomycin A Sigma-Aldrich Cat#75351
Cell-Tak Cell and Tissue Adhesive Corning Cat#C354240
CBR-5884 Cayman Chemicals Cat#19236
NCT-503 Cayman Chemicals Cat#19718
MEGACD40L Protein (soluble) (human), (recombinant) Enzo Life Sciences Cat#ALX-522-110-C010




CellTiter-Glo Luminescent Cell Viability Assay Promega Cat#G7572
BCA Protein Assay Kit Thermo Fisher Cat#23227
Micro BCA Protein Assay Kit Thermo Fisher Cat#23235
NAD/NADH-Glo Assay Promega Cat#G9071
NADP/NADPH-Glo Assay Promega Cat#G9081
Lactate-Glo Assay Promega Cat#J5021
Sea horse XF24 FluxPak Agilent Cat#100850-001
Seahorse XF24 V7 PET Culture Microplates Agilent Cat#101037-004
Deposited Data
Unprocessed peptide files for Figures 1 and S1–S4 This paper https://data.mendeley.com/datasets/
tfg83w73v3/draft?a=be5f697e-07e3-
472a-8b1b-736485b18b08
Raw Mass Spectrometry Data Files This paper Deposited to the ProteomeXchange
Consortium (http://www.proteomexchange.
org/) via the PRIDE partner repository with
the dataset identifier PRIDE: PXD013034.
Experimental Models: Cell Lines
GM12878 Coriell N/A
P493-6 Micah Luftig N/A
2-2-3 EBNA2-HT Bo Zhao
P3HR-1 ZHT/RHT Calderwood et al., 2008 N/A
HEK293T ATCC
Oligonucleotides
GCAAAGAGGAGCTGATAGCG Integrated DNA PHGDH mRNA Forward
TTCTCAGCTGCGTTGATGAC Integrated DNA PHGDH mRNA Reverse
TGGCTGCGACTTCTCTAATGT Integrated DNA MTHFD2 mRNA Forward
CCTTCCAGAAATGACAACAGC Integrated DNA MTHFD2 mRNA Reverse
CGGCTACCACATCCAAGGAA Integrated DNA 18S rRNA Forward
GCTGGAATTACCGCGGCT Integrated DNA 18S rRNA Reverse
GAGCGATCTTGGCAATCTCT Integrated DNA BALF5 vDNA Forward
TGGTCATGGATCTGCTAAACC Integrated DNA BALF5 vDNA Reverse
ACTTCAACAGCGACACCCACTC Integrated DNA GAPDH gDNA Forward
TCTCTTCCTCTTGTGCTCTTGCT Integrated DNA GAPDH gDNA Reverse
CACCGCCTCTTACCGAACTGCCGCG Integrated DNA MTHFD2 sgRNA1 Forward
AAACCGCGGCAGTTCGGTAAGAGGC Integrated DNA MTHFD2 sgRNA1 Reverse
CACCGCCTTCGCCCTTTCCACCTCG Integrated DNA MTHFD2 sgRNA2 Forward
AAACCGAGGTGGAAAGGGCGAAGGC Integrated DNA MTHFD2 sgRNA2 Reverse
(Continued on next page)
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CTTGCAGTGAGCCGAGATT Integrated DNA AluYb8 gDNA Forward
GAGACGGAGTCTCGCTCTGTC Integrated DNA AluYb8 gDNA Reverse
TGTTGGTTATACCCTTCCCGTACTA Integrated DNA MT-ND2 mtDNA Forward
CCTGCAAAGATGGTAGAGTAGATGA Integrated DNA MT-ND2 mtDNA Reverse
T*C*G*T*C*G*T*T*T*T*G*T*C*G*T*T*T*T*G*T*C*G*T*T
(*=phosphorothioate modification)
Integrated DNA CpG ODN 2006
Recombinant DNA
pLX_TRC313-MTHFD2R GenScript N/A
pLX_TRC313-TPNOX Vamsi Mootha, Massachusetts
General Hospital/Howard Hughes
Medical Institute, Boston, USA
N/A
pLX_TRC313-MitoTPNOX Vamsi Mootha, Massachusetts
General Hospital/Howard Hughes
Medical Institute, Boston, USA
N/A
Software and Algorithms
‘‘MassPike’’, a Sequest-based software pipeline for
quantitative proteomics.
Steven Gygi Laboratory, Harvard
Medical School, Boston, USA
N/A
XLStat Addinsoft https://www.xlstat.com/en/
DAVID software Huang da et al., 2009b https://david.ncifcrf.gov/




Java Treeview SourceForge.net http://jtreeview.sourceforge.net/
Natural isotope correction This paper github.com/BrynMarieR/natural_
isotope_correction/
Other
Dialyzed Fetal Bovine Serum Gemini Bio-Products Cat#100-108
Standard Fetal Bovine Serum, Qualified, USDA-
Approved Regions
ThermoFisher Scientific Cat#10437028
RPMI 1640 Medium w/o L-Glutamine, L-Serine,
HEPES (Powder) - 10L
US Biological Cat#R8999-15
1X RPMI-1640 Media without Glucose, Glycine and
Serine. 500mL, Sterile. 2 Pack.
Teknova Cat#R9660-02
RPMI 1640 Medium ThermoFisher Scientific Cat#11875085
HEPES (1M) ThermoFisher Scientific Cat#15630080
RosetteSep Human B Cell Enrichment Cocktail STEMCELL Technologies Cat#15064
EasySep Human B Cell Enrichment Kit STEMCELL Technologies Cat#19054
High Precision Glass Cover Slip, box of 100,
No 1.5, 24x50mm
Bioscience Tools Cat#CSHP-No1.5-24x50
Proxeon EASY-nLC 1000 LC pump ThermoFisher Scientific LC120
Orbitrap Fusion Lumos Mass Spectrometer ThermoFisher Scientific Cat# IQLAAEGAAP FADBMBHQ
LSM 800 with Airyscan Zeiss N/ACONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents may be directed to Benjamin Gewurz (Lead Contact and Corresponding
Author; bgewurz@bwh.harvard.edu) or Michael Weekes (Corresponding Author; mpw1001@cam.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Culture of Established Cell Lines
HEK293Twere cultured in DMEMwith 10% fetal bovine serum (FBS). GM12878 lymphoblastoid cells were derived from a Caucasian
female and were obtained from Coriell. GM12878 Cas9+ cell lines were previously described (Ma et al., 2017). The 2-2-3 EBNA2-HT
conditional EBNA2 allele cell line was a kind gift from Bo Zhao and Elliott Kieff (HarvardMedical School) andmaintained continuouslyCell Metabolism 30, 539–555.e1–e11, September 3, 2019 e4
in the presence of 4-hydroxytamoxifen (4HT). EBNA2-HT cells contain a conditional EBNA2 allele, where EBNA2 is fused to the ligand
binding domain of a modified estrogen receptor that binds to 4HT but is not activated by calf estrogens. In the presence of 4HT,
EBNA2HT localizes to the nucleus, but upon 4HT withdrawal, it relocalizes to the cytosol and is destabilized. To remove 4HT, cells
were washed five times with 4HT-free media with the last two washes 30 minutes each before re-seeding at 300,000 cells per mL.
Cells were then grown for a further 48 hours before harvesting for RNA extraction and cell lysate preparation. The P493-6 cell line was
a kind gift fromMicah Luftig (Duke University). P493-6 cells are LCLs that also contain a conditional EBNA2-HT allele. In addition, they
have an exogenous Tet-OFF MYC allele, where withdrawal of tetracyclines induces high-level MYC expression. P493-6 cells were
maintained continuously in a Burkitt-lymphoma-like state with high exogenous MYC expression by culturing cells in the absence
of doxycycline and in the absence of 4HT. To grow P493-6 cells in the lymphoblastoid cell state (which has intermediate MYC level),
P493-6 cells were grown in the presence of both 1 mM 4HT to induce EBNA2-HT nuclear translocation and 1 mg/mL doxycycline to
suppress exogenous MYC allele expression. In this state, EBNA2 induces endogenous MYC expression. To shift P493-6 cells to a
low EBNA2 and lowMYC state, cells were washed five times and returned to media with 1 mg/mL doxycycline but without 4HT. After
48 hours of growth in any of these conditions, whole cell lysates were prepared. For selection following lentiviral transduction,
hygromycin (Calbiochem) at 200 mg/mL or puromycin (Invitrogen) at 3 mg/mL was used. All cells were cultured in RPMI-1640
(Invitrogen) supplemented with 10% standard FBS and penicillin-streptomycin in a humidified incubator at 37C and at 5% CO2.
All cells were routinely confirmed to be mycoplasma-negative.
Primary Human B-Cell Isolation and Culture
Platelet-depleted venous blood obtained from the Dana-Farber Cancer Institute blood bank were used for primary human B cell
isolation, following our Institutional Review Board-approved protocol for discarded and de-identified samples. RosetteSep and
EasySep negative isolation kits (STEMCELL Technologies) were used sequentially to isolate CD19+ B-cells with the following
modifications made to the manufacturer’s protocols. For RosetteSep, 40 mL of antibody cocktail was added per mL of blood and
then layered onto Lymphoprep density medium for centrifugation. For EasySep, 10 mL of antibody cocktail was added per mL of
B cells, followed by 15 mL of magnetic bead suspension per mL of B cells. After negative selection, the cells obtained were
R95% positive for CD19, a nearly pan-B cell surface marker (CD19 is weakly expressed on plasma cells). For most experiments,
cells were cultured in RPMI-1640 (Invitrogen) supplemented with 10% standard FBS and penicillin-streptomycin. For metabolite
withdrawal and labeling experiments, RPMI-1640 without glucose, serine and glycine (Teknova) was used, and supplemented
with 10% dialyzed FBS (Gemini Biosciences) and penicillin-streptomycin and, if applicable, the appropriate chemical supplement.
Cells were cultured in a humidified incubator at 37C and at 5% CO2.
METHOD DETAILS
EBV Infection of Primary B-Cells
EBV B95-8 virus was produced fromB95-8 cells with conditional ZTA expression. 4HTwas used at a concentration of 1 mM to induce
EBV lytic replication, removed 24 hours later, and cells were resuspended in 4HT-free RPMI/10% FBS for 96 hours. Virus-containing
supernatants were collected and subject to filtration through a 0.45 mm filter to remove producer cells. Titer was determined exper-
imentally by transformation assay. The P3HR-1 EBV strain was produced by using a P3HR-1 cell line with conditional 4HT-responsive
ZTA-HT and RTA-HT alleles, a kind gift fromDrs. Eric Johannsen and Elliott Kieff (Ersing et al., 2017; Calderwood et al., 2008). P3HR1
ZHT/RHT cells were induced with 1 mM of 4HT for 24 hours. RPMI/FBS media was then exchanged for fresh media, and viral super-
natants were collected from induced cultures 96 hours thereafter. Viral supernatants were purified by filtration through a 0.45 mM
filter. Genomic DNA content of preparations of this non-transforming virus were quantitated by PCR for BALF5 on total DNA ex-
tracted, and cross-compared with levels from B95-8 preparation, which were also measured by this approach in a parallel assay
at the same time, in order to normalize input virus amounts for subsequent cell infection studies. The plasmid pHAGE-BALF5 was
used for standard curves. Calculated genome copy numbers were used to normalize B95-8 and P3HR-1 amounts used for de
novo infection cross-comparison studies. UV irradiation of B95-8 virus supernatants was performed at a cumulative intensity of
3J per square centimeter on ice, to prevent heat-induced virus degradation. To validate equal B95-8 and P3HR-1 uptake 24 hours
post-infection, cells were extensively washed in PBS and then total DNA was extracted from newly infected cells and used for the
BALF5 qPCR assay described above. Immunofluorescence analysis was done for EBNA1 at 48 hours post-infection to further
validate equal infection.
Agonist Stimulation of Primary B-Cells
Freshly isolated primary B-cells were seeded in complete RPMI media and 10% FBS at 1 million cells per mL. The following agonists
were used at these indicated concentrations: MEGACD40L (50 ng/mL), aIgM (1 mg/mL), CpG (1 mM) and IL-4 (20 ng/mL). Cells were
harvested at 24 hours and 96 hours for whole cell lysate preparation. For the latter timepoint, agonist replenishment was performed
without removal of the spent media at 48 hours.
Cell Preparation for Three Biological Replicates of TMT Proteomic Analysis
Using the protocols listed in the Experimental Models section, primary human B-cells were purified by negative selection. For each of
three biological replicates, B-cells were isolated from four anonymous human donors. Although we routinely achieved CD19+ B-celle5 Cell Metabolism 30, 539–555.e1–e11, September 3, 2019
purity >95%, we cultured B-cell preparations from each donor separately, to eliminate the chance of allo-responses from rare
co-purifying T-cells between donor cells. With respect to the transformation time course, uninfected B-cells (for the 0 DPI timepoint)
were stained with propidium iodide and anti-CD19 antibody, and FACSort was performed for live (based on forward and side scatter
parameters) CD19+ B-cells on a BD FACSAria cytometer at the Brigham &Women’s Hospital Flow Cytometry core facility, to control
for effects of FACSsort at subsequent timepoints. EBV was added to the remaining purified B-cells at an MOI of 0.1 (approximately
250 mL of supernatant from ZHT cells 5 days after ZHT stimulation, with washout of 4HT after 24 hours, per million purified B-cells).
Cells were cultured in a humidified chamber at 37 degrees in complete growth media, again maintaining cultures from each B-cell
donor in separate flasks. At each indicated time point, cells from each donor were stained with antibody against CD23, a surrogate
marker of EBV-infected cells upregulated by EBNA2 early after EBV infection. Live (based on forward and side scatter gates) CD23+
cells were sorted on the same BD FACSAria cytometer. Whole cell lysates (WCL) and plasma membrane (PM) samples were
prepared as described in ‘‘WCL and PM protein preparation for TMT-based proteomics’’. Samples from each donor were sorted
sequentially. Immediately following the sort, cells were lysed as described below forWCL analysis or subjected to plasmamembrane
profiling. Samples were combined at constant ratios at the cell lysis step. The three proteomic time course biological replicates were
performed at least one month apart.
Protein Preparation for TMT-Based Proteomics
Plasma membrane profiling was performed as described previously (Weekes et al., 2014, 2012). Briefly, FACS sorted B-cells were
washed twice with ice-cold PBS. Sialic acid residues were oxidized with sodium meta-periodate (Thermo Fisher) then biotinylated
with aminooxy-biotin (Biotium). The reaction was quenched, cell numbers for each condition were normalized to 2 x 106 using a
BioRad TC20 automated cell counter and the biotinylated cells were lysed in 1.6% Triton X-100 lysis buffer. Biotinylated glycopro-
teins were enriched with high affinity streptavidin agarose beads (Pierce) and washed extensively. Captured protein was denatured
with DTT, alkylated with iodoacetamide (IAA, Sigma) and digested on-bead with trypsin (Promega) in 200 mM HEPES pH 8.5 for 3h.
Tryptic peptides were collected.
For whole proteome samples, cells were washed twice with PBS, and 150 ul of 6M guanidine/50 mM HEPES pH 8.5 lysis buffer
added. Samples were vortexed extensively then sonicated. Cell debris was removed by centrifuging at 13,000 g for 10 min twice.
Dithiothreitol (DTT) was added to a final concentration of 5mM and samples were incubated for 20 min. Cysteines were alkylated
with 15mM iodoacetamide and incubated 20 min at room temperature in the dark. Excess iodoacetamide was quenched with
DTT for 15 min. Samples were diluted with 200 mM HEPES pH 8.5 to 1.5 M guanidine, followed by digestion at room temperature
for 3 hr with LysC protease at a 1:100 protease-to protein ratio. Trypsin was then added at a 1:100 protease-to-protein ratio followed
by overnight incubation at 37oC. The reaction was quenched with 1% formic acid, samples were spun at 21,000g for 10 min to re-
move debris and undigested protein, then subjected to C18 solid-phase extraction (Sep-Pak, Waters) and vacuum centrifuged to
near-dryness
In preparation for TMT labelling, desalted peptides were dissolved in 200 mM HEPES pH 8.5. For whole proteome samples, pep-
tide concentration was measured by micro BCA (Pierce), and 50 mg of peptide labelled with TMT reagent. For plasma membrane
samples, 100% of each peptide sample was labelled. TMT reagents (0.8 mg) were dissolved in 43 ml anhydrous acetonitrile and
5 ml added to peptide sample at a final acetonitrile concentration of 30% (v/v). Samples were labelled as follows: Experiment
WCL1: CD19+ uninfected (TMT 126); CD23+ infected d1 (TMT 127N); CD23+ infected d2 (TMT 127C); CD23+ infected d4 (TMT
128N); CD23+ infected d7 (TMT 128C); CD23+ infected d10 (TMT 129N); CD23+ infected d14 (TMT 129C); CD23+ infected d18
(TMT 130N); CD23+ infected d21 (TMT 130C); CD23+ infected d28 (TMT 131). For Experiment WCL2: CD19+ uninfected (TMT
126); CD23+ infected d2 (TMT 127N); CD23+ infected d4 (TMT 127C); CD23+ infected d7 (TMT 128N); CD23+ infected d10 (TMT
128C); CD23+ infected d14 (TMT 129N); CD23+ infected d18 (TMT 129C); CD23+ infected d21 (TMT 130N); CD23+ infected d28
(TMT 130C); CD23+ infected d35 (TMT 131). Experiment WCL3: CD19+ uninfected (TMT 126); CD23+ infected d2 (TMT 127N);
CD23+ infected d4 (TMT 127C); CD23+ infected d7 (TMT 128N); CD23+ infected d10 (TMT 128C); CD23+ infected d14 (TMT
129N); CD23+ infected d18 (TMT 129C); CD23+ infected d21 (TMT 130N); CD23+ infected d24 (TMT 130C); CD23+ infected d28
(TMT 131). Experiment PM1: CD19+ uninfected (TMT 126); CD23+ infected d2 (TMT 127N); CD23+ infected d4 (TMT 127C);
CD23+ infected d7 (TMT 128N); CD23+ infected d10 (TMT 128C); CD23+ infected d14 (TMT 129N).
Following incubation at room temperature for 1 hr, the reaction was quenched with hydroxylamine to a final concentration of 0.5%
(v/v). TMT-labeled samples were combined at a 1:1:1:1:1:1:1:1:1:1 ratio. The sample was vacuum-centrifuged to near dryness and
subjected to C18 solid-phase extraction (SPE) (Sep-Pak, Waters).
Offline high pH reversed-phase fractionation of peptides from experiments WCL1-3, and offline tip-based strong cation exchange
fractionation of the PM sample were performed, andWCL peptide fractions combined as described previously (Weekes et al., 2014).
Peptide Fragmentation and Detection by LC-MS3
Mass spectrometry data were acquired using an Orbitrap Lumos coupled with a Proxeon EASY-nLC 1000 LC pump (Thermo Fisher
Scientific, San Jose, CA). Peptideswere separated on a 75mm inner diametermicrocapillary column packedwith 0.5 cmofMagic C4
resin (5 mm, 100 A, Michrom Bioresources) followed by approximately 20 cm of GP118 resin (1.8 mm, 120 A, Sepax Technologies).
Peptideswere separated using a 3 hr gradient of 6 to 30%acetonitrile in 0.125% formic acid at a flow rate of 300 nl/min. Each analysis
used anMS3-based TMTmethod (McAlister et al., 2012; Ting et al., 2011). The scan sequence beganwith anMS1 spectrum (OrbitrapCell Metabolism 30, 539–555.e1–e11, September 3, 2019 e6
analysis, resolution 120,000, 350-1400 Th, AGC target 5 x 105, maximum injection time 100 ms). ‘Rapid’ was selected for MS2
analysis, which consisted of CID (quadrupole ion trap analysis, AGC 1.8 x 104, NCE 35, maximum injection time 120 ms). For
MS3 analysis, precursors were fragmented by HCD prior to Orbitrap analysis (NCE 55, max AGC 2 x 105, maximum injection time
150 ms, isolation specificity 0.7 Th, resolution 50,000).
Analysis of LC-MS3 Data
Mass spectra were processed using a Sequest-based in-house software pipeline as described previously (Weekes et al., 2014).
Briefly, MS spectra were converted to mzXML using a modified version of ReAdW.exe. A combined database was constructed
from (a) the human Uniprot database (February 4th, 2014), (b) B95-8 strain EBV (see ‘Database Generation’ section), (c) all open
reading frames from a six-frame translation of B95-8 strain EBV and (d) common contaminants such as porcine trypsin and endo-
proteinase LysC. The combined database was concatenated with a reverse database composed of all protein sequences in reversed
order. Searcheswere performed using a 20 ppmprecursor ion tolerance. Product ion tolerancewas set to 0.03 Th. TMT tags on lysine
residues and peptide N termini (229.162932 Da) and carbamidomethylation of cysteine residues (57.02146 Da) were set as static
modifications, while oxidation of methionine residues (15.99492 Da) was set as a variable modification. To control the fraction of erro-
neous protein identifications, we used a target-decoy strategy (Elias and Gygi, 2007, 2010). Peptide spectral matches (PSMs) were
filtered to an initial peptide-level false discovery rate (FDR) of 1% with subsequent filtering to attain a final protein-level FDR of 1%.
PSM filtering was performed using a linear discriminant analysis, as described previously (Huttlin et al., 2010), considering the
following parameters: XCorr, DCn, missed cleavages, peptide length, charge state, and precursor mass accuracy. Protein assembly
was guided by principles of parsimony to produce the smallest set of proteins necessary to account for all observed peptides. Data
for all three biological WCL replicates and the PM analysis were initially filtered and assembled together to produce a single list of
quantified proteins.
Proteins were quantified by summing TMT reporter ion counts across all matching peptide-spectral matches using in-house
software, as described previously (Pease et al., 2013). Briefly, a 0.003 Th window around the theoretical m/z of each reporter
ion (126, 127N, 127C, 128N, 128C, 129N, 129C, 130N, 130C, 131) was scanned for ions, and the maximum intensity nearest to
the theoretical m/z was used. We required every individual peptide used for quantitation to contribute sufficient TMT reporter
ions (minimum of 1,250 per spectrum) so that each on its own provided a representative picture of relative protein abundance
(McAlister et al., 2012). We additionally employed an isolation specificity filter to minimize peptide coisolation (Ting et al.,
2011). Peptide-spectral matches with poor quality MS3 spectra (more than 9 TMT channels missing and/or a combined
signal:noise ratio of less than 250 across all TMT reporter ions) or no MS3 spectra at all were excluded from quantitation. Protein
quantitation values were exported for further analysis in Excel. For protein quantitation, reverse and contaminant proteins were
removed, then each reporter ion channel was summed across all quantified proteins and normalized assuming equal
protein loading across all 10 samples. Gene Ontology terms were downloaded from www.Uniprot.org. XLStat (Addinsoft) was
used to determine the number of distinct k-means clusters (Figure S1D). Hierarchical centroid clustering was based on Euclidian
Distance. Hierarchical and k-means clustering were performed using Cluster 3.0 (Stanford University) and visualized using Java
Treeview (http://jtreeview.sourceforge.net).
Pathway Analysis was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) (Huang da
et al., 2009b) version 6.8 with default settings. A given cluster was always searched against a background of all proteins quantified
within the relevant experiment. To generate lists of proteins for DAVID enrichment analysis, for WCL data, proteins were included if
they were quantified in all three experiments WCL1-3. For Figure 1D, parent terms were either derived from a hierarchical structure in
Uniprot, or Gene Ontology (http://supfam.org/SUPERFAMILY/cgi-bin/go.cgi).
Gene Set Enrichment Analysis (GSEA)
The difference in the proteomics data from uninfected cells was used to generate a ranked list for GSEA Preranked analysis
using the Molecular Signatures Database v5.2 (C7:immunologic signatures) (Subramanian et al., 2005). Gene sets with nominal
p value < 0.05 and false discovery rate (FDR) <0.25 were defined as significantly enriched gene sets, which were selected for
visualization.
LC-MS Metabolite Analysis
Cells were seeded at 1 million cells/mL with fresh media (containing labeled amino acids, if required) 24 hours prior to harvesting. To
prepare cellular metabolite extracts, cells were washed once with ice-cold PBS and once with ice-cold 100 mM ammonium acetate
before lysis with acetonitrile-methanol-water (27:9:1). For detection of cellular M+3 serine with U13C-glucose, the same procedure
was used with the labeling period shortened to 4 hours to minimize exchange between cellular serine and media serine. For nicotin-
amide dinucleotide hydride labeling, we followed the protocol described by Fan et al. (2014) and Zhang et al. (2017), which did not
involve natural isotope correction. Briefly, 1 million cells were labeled with serine-free media supplemented by 285 mM [2,3,3-2H]-
serine for 4 hours, and cell pellets were lysed directly in 200 mL ice-cold acetonitrile-methanol-water (27:9:1) containing 0.1 M formic
acid. Wash steps were omitted to avoid hydride exchange. Lysates were immediately neutralized with 17.5 mL of 15% (w/v) ammo-
nium bicarbonate solution (within 15 seconds of lysis buffer addition) and centrifuged at maximum speed for 20 min at 4C.
Supernatants were analyzed on the same day by the ZIC-pHILIC method mentioned below. To prepare media metabolite extracts,
50 mL of media was extracted with acetonitrile-methanol (3:1). All extraction steps were performed at 4C. Crude extracts weree7 Cell Metabolism 30, 539–555.e1–e11, September 3, 2019
centrifuged at maximum speed at 4C for 20 minutes to remove cellular debris, and supernatants were either used immediately or
frozen at -80C for short-term storage. LC/MS-based analyses were performed on a Q Exactive Plus orbitrap mass spectrometer
equipped with an Ion Max source and a HESI II probe, which was coupled to a Dionex UltiMate 3000 UPLC system (Thermo Fisher
Scientific).
Polar metabolites in the spent media and cellular extracts were analyzed using Xbridge BEH Amide XP HILIC 2.5 mm,
2.1 mm x 100 mm column (Waters) with the guard column and SeQuant ZIC-pHILIC Polymeric 5 mm, 150 x 2.1 mm column
(EMD-Millipore).
For the amide method, the mobile phase A was 5% acetonitrile, 20mM ammonium acetate/ammonium hydroxide, pH 9. The mo-
bile phase B was 100% acetonitrile. The flow rate was 220 ml/min from 0 – 15 min, and 420 ml/min from 15 – 25 min. The gradient was
as follows: 0min: 85%B; 0.5min: 85%B; 9min: 35%B; 11min: 2%B; 13.5min: 85%B; 15min: 85%B; 22min: 85%B. TheMS data
was collected in the polarity switching mode with full scan mode in a range of 70–1000 m/z, with the resolution at 70,000, the
AGC target at 1E6, and the maximum injection time at 80 ms, the sheath gas flow at 50 units, the auxiliary gas flow at 10 units,
the sweep gas flow at 2 units, the spray voltage at 2.5 kV, the capillary temperature at 310 C, and the auxiliary gas heater temper-
ature at 370C.
For dTTP, AMP, GSH and GSSG using the ZIC-pHILIC method, the mobile phase A was 20mM ammonium carbonate/ammonium
hydroxide, pH 9.6. Themobile phase Bwas 100% acetonitrile. The flow rate was 150 ml/min. The gradient was as follows: 0min: 80%
B; 0.5min: 80%B; 20.5min: 20%B; 21.5min: 80%B; 29min: 80%B. TheMS data acquisition was collected in the polarity switching
mode with full scan mode in a range of 70–1000m/z, with the resolution at 70,000, the AGC target at 1E6, and the maximum injection
time at 80 ms with the same parameters mentioned above.
For NAD(P)+ and NAD(P)H using the ZIC-pHILIC method, the mobile phase A was 20mM ammonium carbonate/ammonium
hydroxide, pH 9.6. The mobile phase B was 100% acetonitrile. The flow rate was 110 ml/min. The gradient was as follows: 0 min:
80% B; 2 min: 80% B; 18 min: 62% B; 25 min: 20% B; 26 min: 80% B; 37 min: 80% B. The MS data was collected in the negative
polarity mode with full scan mode in a range of 300–1000m/z, with the resolution at 70,000, the AGC target at 3E6, and the maximum
injection time at 400 ms, and the same parameters mentioned above.
Progenesis QI software (Waters, NC) and Xcalibur (Thermo Fisher Scientific) were used to analyze the data. Absolute quantification
of glucose, serine and lactate in the spent media was measured by comparing to the 13C-labeled internal standards at different
spiked concentrations.
Natural Isotope Correction
Mass isotopologue distributions were corrected for the natural abundance of heavy isotopes of hydrogen, carbon, oxygen, and
nitrogen. Phosphorus is considered monoisotopic. Natural abundances were found in the Table of Isotopic Compositions of the
Elements (TICE) maintained by the International Union of Pure and Applied Chemistry (IUPAC) (Meija et al., 2016).Element M+0 M+1 M+2
H 0.999885 0.000115
C 0.9893 0.0107
O 0.99757 0.00038 0.00205
N 0.99632 0.00368
P 1This method takes into account the different isotope abundance distributions in the labeled molecule as compared to the isotope
abundance distributions in the unlabeled molecule (the proportionality ‘‘skew’’). The corrected mass isotopologue distribution
MIDcorr is obtained by multiplying the observed mass isotopologue distribution (MIDobs) by a correction matrix (CM); the CM for
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Where N is the number of atoms of the element (in this case, oxygen) in the molecule, n is the number of naturally occurring iso-
topes, I1,. In, of the element, p(Ii) gives the natural abundance of isotope Ii, and f(Ii) is the frequency of the i-th isotope in themolecule.















































We used a least-squares implementation of the accepted optimal approach for natural abundance correction, the ‘‘skewed’’
method as outlined by Midani et al. in reference to earlier works by Rosenblatt and Fernandez et al. (Midani et al., 2017; Fernandez
et al., 1996; Rosenblatt et al., 1992). The R package nnls was used to find the non-negative least squares solution. Details of algo-
rithmic implementation were adapted from Yang et al. (Yang et al., 2009). Full code is available online at github.com/BrynMarieR/
natural_isotope_correction/.
Flow Cytometry Analysis
Flow cytometry studies (FACS) were performed on a BD FACSCalibur instrument. Cells were washed once with cold PBS supple-
mented with 0.5% bovine serum albumin (BSA). Cells were then incubated with a 1:100 dilution of fluorophore-conjugated primary
antibody (and, if applicable, a 1:500 dilution of fluorophore-conjugated secondary antibody) in PBS with 0.5% BSA for 1 hour. Cells
were pelleted and resuspended in 400 mL of PBS, strained into flow cytometry-compatible tubes and processed immediately with a
flow cytometer. Sample processing was performed either immediately or within 24 hours after staining.
For DCFDA staining, cells were treated with 10 mM DCFDA in complete media for 20 minutes before processing with the flow cy-
tometer. As a positive control, pre-treatment of cells with 100 mM tert-butyl hydrogen peroxide (TBHP) for 3 hours was performed. For
JC-1 staining, cells were treated with 10 mM JC-1 in complete media for 15 minutes before processing with the flow cytometer. As a
positive control, concurrent treatment of cells with 100 mM CCCP was performed. For 2-NBDG staining, cells were incubated with
10 mg/mL 2-NBDG in complete media for one hour at 37C. For CFSE staining, 4 DPI cells and GM12878 LCLs were stained with
10 mM CFSE for 15 minutes at 37C, washed and resuspended at 100 000 cells/mL. For 7-AAD staining, cells were stained with
1 mM 7-AAD at room temperature for 5 minutes before being placed at ice until further processing with the flow cytometer. For pro-
pidium iodide staining, 7DPI cells andGM12878 LCL fixed in ice-cold 90%ethanol/PBS for at least two dayswere re-hydrated in PBS
and stained with a solution of 20 mg/mL propidium iodide, 40 mg/mL RNase A and 1:1000 (v/v) Triton X-100 for 30 minutes before
immediate processing by the flow cytometer.
Flow cytometric data was acquired with a BD FACSCalibur instrument in most instances (with the exception of the CFSE and
7-AAD experiments, whose data were acquired with a BD FACSCanto I flow cytometer) and analysis was performed with FlowJo.
Immunofluorescence Microscopy
Approximately 1 million cells were pelleted and resuspended in 1-2 mL PBS and streaked onto glass slides to dry. Cells were fixed
with 4% paraformaldehyde/PBS solution for 10 minutes and permeabilized with 0.5% (v/v) Triton X-100/PBS solution for 5 minutes,
with PBS washing in between and after each of those steps. Cells were incubated with 20% normal goat serum (NGS) blocking re-
agent for 1 hour. EBNA1-specific OT1x antibody was diluted 1:100 in the blocking reagent and added to cells for 1 hour. Cells were
washed and incubated with Alexa Fluor 488-conjugated goat anti-mouse secondary antibody (diluted 1:1000 in blocking reagent) for
30 minutes. Cells were washed and incubated with a 10 mg/mL Hoechst 33258/PBS solution for 3-5 minutes. Cells were washed ande9 Cell Metabolism 30, 539–555.e1–e11, September 3, 2019
successively dehydrated in 70% (1 minute), 90% (1 minute) and 100% ethanol (1 minute). ProLong Gold antifade reagent was added
to each well and a No. 1.5 coverslip was attached. Data acquisition was performed using a Zeiss LSM 800 instrument. Processing
and analysis were performed using ZEN Blue software (Zeiss). All steps were performed at room temperature.
In Vitro Transformation Assays
Freshly isolated primary human B-cells, purified as outlined above by negative selection, were seeded into 96-well plates at a density
of 500,000 cells/mL in 100 mL per well of RPMI/10% FBS. B95-8 virus supernatant (see section entitled, ‘‘EBV infection of primary
B-cells’’, for details) was diluted ten-fold to give a five-point dilution series. To each well, 100 mL of virus supernatant was added.
DMSO vehicle, MTH-1479 or SHIN1 were added at the indicated concentrations (5 or 10 mM). Vehicle or drug were refreshed every
3 to 4 days by carefully aspirating 100 mL of spent media and replenishing with fresh drug-containing media. At four weeks post-
infection, the proportion of wells with B-cell outgrowth was plotted against the dilution of virus supernatant used per well, as previ-
ously described (Henderson et al., 1977). One transforming unit per well was defined as the amount of virus required to attain B-cell
outgrowth in 62.5% of wells.
Growth Curve Analysis
Newly infected B-cells were seeded at 500,000 cells per well in a volume of 1 mL of RPMI/FBS and grown for two days before mea-
surements of cell numbers were made. For GM12878 lymphoblastoid cells, 100,000 cells were seeded per well in a volume of 1mL
and grown for two days prior to measurements of live cell number. For live cell measurements, cells were pelleted and resuspended
in the same volume of media, trypan blue was added, and live cell number was quantitated with the TC20 automatic cell counter
(Bio-Rad). After measurements were taken, cells were passaged accordingly to give 100,000 cells per mL in RPMI/10% FBS and
grown for two more days. The same procedure was repeated to obtain measurements at later time points. At each time point, cells
were treated with the appropriate inhibitor and/or rescue metabolite(s) at the indicated concentrations after passaging.
CRISPR Editing in GM12878 LCL
Single guide RNA (sgRNA) constructs were generated as previously described (Jiang et al., 2018) using sgRNA sequences from the
Broad Institute Avana Library. The MTHFD2R cDNA rescue construct utilizes the pLX_TRC313 (HygR) vector backbone and was syn-
thesized and sequence-validated by GenScript. C166T and G349A silent point mutations were introduced into the MTHFD2 cDNA
sequence to produce synonymous mutations that conferred resistance to sgRNA #1 and sgRNA #2, respectively.
LCL CRISPR editing was performed as previously described (Jiang et al., 2018). Briefly, lentiviruses encoding sgRNAswere gener-
ated by transient transfection of 293T cells with packaging plasmids and pLentiGuide-Puro plasmids. GM12878 cells stably express-
ing Cas9 were transduced with the lentiviruses and selected with 3 mg/mL puromycin for three days before replacement with
antibiotic-free media. For rescue experiments or cDNA overexpression, 293T cells were transiently transfected to produce lentivi-
ruses that carry the rescue or control GFP cDNA and a hygromycin resistance marker. GM12878 cells were transduced with
293T rescue lentivirus supernatants at 48 and 72 hours post-293T cell transfection, and selected into RPMI/10% FBS with
200 mg/mL hygromycin 48 hours later. Cells were hygromycin selected for at least one week before transduction with sgRNA-encod-
ing lentiviruses. CRISPR editing and rescue cDNA expression were confirmed by immunoblot.
Kit-Based Quantitation of ATP, NAD(P)H and Extracellular Lactate
Cells were assayed using commercially available kits (Promega), namely CellTiter-Glo (ATP measurements), NADH-Glo (NADH and
NAD+ measurements), NADPH-Glo (NADPH and NADP+ measurements) and Lactate-Glo, accordingly to manufacturer’s
instructions.
Quantitative PCR
RT-qPCR analysis of mRNA abundance was performed on a BioRad CFX Connect Real-time PCR detection system, using Power
SYBR Green RNA-to-CT 1-Step Kit (Applied Biosystems) for 40 cycles. Expression values relative to 18S rRNA expression were
calculated using CFX Manager Software. Quantitative PCR of viral genome copies utilized host cell GAPDH gene copy number as
control. To quantitatemitochondrial DNA copy number, total cellular DNAwas extracted using the DNAeasy kit (Qiagen). Quantitative
PCRwas then performed on 10 ng input DNA usingMT-ND2 (mtDNA)-specific and AluYb8 (nuclear DNA)-specific primers. Ct values
obtained fromAluYb8 amplification were used for normalization. A list of PCR primers used can be found in the Key Resources Table.
Mitochondrial Stress Test
Cell culture plates were layered with Cell-Tak to enable adhesion of the B-cells. Cells were seeded at 500,000 per well. For standard
measurements, complete bicarbonate-free RPMI-1640 supplementedwith 25mMHEPES, 10%dialyzed FBS and 2mML-glutamine
was used as the growthmedia during the period of data acquisition. For serinewithdrawal and subsequent rescue experiments, com-
plete bicarbonate- and serine-free RPMI-1640 supplemented with 25 mM HEPES, 10% dialyzed FBS and 2 mM L-glutamine was
used, with serine and formate added accordingly to the appropriate wells. Detection of changes in oxygen consumption and extra-
cellular acidification rates was achieved with the use of Seahorse XF24 sensor cartridges. The following mitochondrial poisons were
used: 3.5 mMoligomycin, 2 mMCCCP and 100 nM piericidin A. Data acquisition was performed with the Seahorse XF24 Extracellular
Flux Analyzer (Agilent).Cell Metabolism 30, 539–555.e1–e11, September 3, 2019 e10
QUANTIFICATION AND STATISTICAL ANALYSIS
The exact value of replicates (n) is indicated in the figure legends and refers to the number of biological replicates. Blinding or sample-
size estimation was not appropriate for this study. There were no inclusion criteria and no data was excluded. Unless stated
otherwise, Student’s t-test was performed for all experiments. GraphPad Prism was used to plot data and to perform subsequent
statistical analysis. FlowJo was used to process and analyze flow cytometry data.
DATA AND SOFTWARE AVAILABILITY
Unprocessed peptide data files for Figures 1 and S1–S4 are available at https://data.mendeley.com/datasets/tfg83w73v3/draft?
a=be5f697e-07e3-472a-8b1b-736485b18b08. These files include details of peptide sequence, redundancy, protein assignment
raw unprocessed TMT reporter intensities and isolation specificity. The mass spectrometry proteomics data have been deposited
to the ProteomeXchange Consortium (http://www.proteomexchange.org/) via the PRIDE partner repository. The accession number
for the mass spectrometry proteomics data reported in this paper is PRIDE :PXD013034.e11 Cell Metabolism 30, 539–555.e1–e11, September 3, 2019
